Marks Group Wealth Management Inc Acquires 276 Shares of Danaher Co. (NYSE:DHR)

Marks Group Wealth Management Inc increased its holdings in Danaher Co. (NYSE:DHR) by 7.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,971 shares of the conglomerate’s stock after acquiring an additional 276 shares during the quarter. Marks Group Wealth Management Inc’s holdings in Danaher were worth $919,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. BKM Wealth Management LLC purchased a new stake in Danaher during the 4th quarter valued at about $27,000. Wetzel Investment Advisors Inc. purchased a new stake in Danaher during the 4th quarter valued at about $29,000. OFI Invest Asset Management purchased a new stake in Danaher during the 3rd quarter valued at about $30,000. Rakuten Securities Inc. purchased a new stake in Danaher during the 4th quarter valued at about $36,000. Finally, Nalls Sherbakoff Group LLC purchased a new stake in Danaher during the 3rd quarter valued at about $37,000. 79.05% of the stock is currently owned by institutional investors.

Danaher Price Performance

Shares of Danaher stock traded up $17.80 on Tuesday, hitting $253.88. 3,947,961 shares of the company traded hands, compared to its average volume of 2,737,833. The stock has a market capitalization of $188.01 billion, a P/E ratio of 39.46, a price-to-earnings-growth ratio of 3.95 and a beta of 0.83. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.37 and a current ratio of 1.68. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $259.00. The business has a 50-day simple moving average of $248.72 and a 200 day simple moving average of $230.39.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.18. The firm had revenue of $6.41 billion for the quarter, compared to analysts’ expectations of $6.10 billion. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The company’s revenue for the quarter was down 10.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.87 earnings per share. Research analysts expect that Danaher Co. will post 7.62 earnings per share for the current fiscal year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be given a dividend of $0.27 per share. The ex-dividend date is Wednesday, March 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.43%. This is a boost from Danaher’s previous quarterly dividend of $0.24. Danaher’s dividend payout ratio (DPR) is presently 16.90%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. KeyCorp raised their price target on shares of Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, February 1st. Raymond James raised their price target on shares of Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. Citigroup raised their price objective on shares of Danaher from $255.00 to $280.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. Barclays raised their price objective on shares of Danaher from $240.00 to $260.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 10th. Finally, Royal Bank of Canada raised their price objective on shares of Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Six research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and a consensus target price of $268.27.

Insider Activity

In related news, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the sale, the senior vice president now owns 38,102 shares in the company, valued at $9,601,704. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, SVP Georgeann Couchara sold 2,622 shares of the business’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total value of $636,280.74. Following the sale, the senior vice president now owns 4,244 shares in the company, valued at $1,029,891.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the sale, the senior vice president now owns 38,102 shares in the company, valued at approximately $9,601,704. The disclosure for this sale can be found here. Insiders have sold a total of 32,957 shares of company stock worth $8,265,802 over the last quarter. Insiders own 10.90% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.